PIK3CA H1047R
PIK3CA H1047R
|
Hepatocellular Cancer
HCC
|
PIK3CA H1047R
PIK3CA H1047R
|
Hepatocellular Cancer
HCC
|
palbociclib + alpelisib
Sensitive: D – Preclinical
Cell Death Dis - 1 week
|
palbociclib + alpelisib
Sensitive: D – Preclinical
Cell Death Dis - 1 week
|
PIK3CA H1047R
PIK3CA H1047R
|
Hepatocellular Cancer
HCC
|
PIK3CA H1047R
PIK3CA H1047R
|
Hepatocellular Cancer
HCC
|
alpelisib + TAK-228
Sensitive: D – Preclinical
Cell Death Dis - 1 week
|
alpelisib + TAK-228
Sensitive: D – Preclinical
Cell Death Dis - 1 week
|
PIK3CA H1047R
PIK3CA H1047R
|
Hepatocellular Cancer
HCC
|
PIK3CA H1047R
PIK3CA H1047R
|
Hepatocellular Cancer
HCC
|
alpelisib
Resistant: D – Preclinical
Cell Death Dis - 1 week
|
alpelisib
Resistant: D – Preclinical
Cell Death Dis - 1 week
|
PIK3CA H1047R
PIK3CA H1047R
|
|
PIK3CA H1047R
PIK3CA H1047R
|
|
cetuximab
Resistant: C3 – Early Trials
|
cetuximab
Resistant: C3 – Early Trials
|
PIK3CA H1047R
PIK3CA H1047R
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
PF-05212384 + Herzuma (trastuzumab biosimilar)
Sensitive: C3 – Early Trials
|
PF-05212384 + Herzuma (trastuzumab biosimilar)
Sensitive: C3 – Early Trials
|
PIK3CA H1047R
PIK3CA H1047R
|
Non Small Cell Lung Cancer
NSCLC
|
PIK3CA H1047R
PIK3CA H1047R
|
Non Small Cell Lung Cancer
NSCLC
|
trametinib + dabrafenib
Sensitive: C3 – Early Trials
|
trametinib + dabrafenib
Sensitive: C3 – Early Trials
|
PIK3CA H1047R
PIK3CA H1047R
|
Breast Cancer
Breast Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Breast Cancer
Breast Cancer
|
TAS-117
Sensitive: C3 – Early Trials
|
TAS-117
Sensitive: C3 – Early Trials
|
PIK3CA H1047R
PIK3CA H1047R
|
|
PIK3CA H1047R
PIK3CA H1047R
|
|
dabrafenib
Sensitive: C4 – Case Studies
|
dabrafenib
Sensitive: C4 – Case Studies
|
PIK3CA H1047R
PIK3CA H1047R
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
everolimus
Sensitive: C4 – Case Studies
|
everolimus
Sensitive: C4 – Case Studies
|
PIK3CA H1047R
PIK3CA H1047R
|
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Anaplastic Carcinoma
|
PIK3CA H1047R
PIK3CA H1047R
|
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Anaplastic Carcinoma
|
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
|
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
|
PIK3CA H1047R
PIK3CA H1047R
|
Salivary Gland Cancer
Salivary Gland Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Salivary Gland Cancer
Salivary Gland Cancer
|
vandetanib
Sensitive: C4 – Case Studies
|
vandetanib
Sensitive: C4 – Case Studies
|
PIK3CA H1047R
PIK3CA H1047R
|
Colon Cancer
Colon Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Colon Cancer
Colon Cancer
|
PF-05212384
Sensitive: D – Preclinical
|
PF-05212384
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
trametinib
Sensitive: D – Preclinical
|
trametinib
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Endometrial Cancer
Endometrial Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Endometrial Cancer
Endometrial Cancer
|
MEN1611
Sensitive: D – Preclinical
|
MEN1611
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
|
PIK3CA H1047R
PIK3CA H1047R
|
|
MEN1611
Sensitive: D – Preclinical
|
MEN1611
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Breast Cancer
Breast Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Breast Cancer
Breast Cancer
|
trastuzumab + lapatinib
Resistant: D – Preclinical
|
trastuzumab + lapatinib
Resistant: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Breast Cancer
Breast Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Breast Cancer
Breast Cancer
|
trastuzumab + MEN1611
Sensitive: D – Preclinical
|
trastuzumab + MEN1611
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Breast Cancer
Breast Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Breast Cancer
Breast Cancer
|
GDC-0941
Sensitive: D – Preclinical
|
GDC-0941
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine
Sensitive: D – Preclinical
|
ado-trastuzumab emtansine
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Head and Neck Cancer
Head and Neck Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Head and Neck Cancer
Head and Neck Cancer
|
alpelisib
Sensitive: D – Preclinical
|
alpelisib
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Ovarian Cancer
Ovarian Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Ovarian Cancer
Ovarian Cancer
|
MEN1611
Sensitive: D – Preclinical
|
MEN1611
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Ovarian Cancer
Ovarian Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Ovarian Cancer
Ovarian Cancer
|
LX-086
Sensitive: D – Preclinical
|
LX-086
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Head and Neck Cancer
Head and Neck Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
Head and Neck Cancer
Head and Neck Cancer
|
SHR-A1307
Sensitive: D – Preclinical
|
SHR-A1307
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Anaplastic Carcinoma
|
PIK3CA H1047R
PIK3CA H1047R
|
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Anaplastic Carcinoma
|
MK-2206
Sensitive: D – Preclinical
|
MK-2206
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
|
PIK3CA H1047R
PIK3CA H1047R
|
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
|
LX-086
Sensitive: D – Preclinical
|
LX-086
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
GDC-0941
Resistant: D – Preclinical
|
GDC-0941
Resistant: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
BMS-722782
Resistant: D – Preclinical
|
BMS-722782
Resistant: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PF-3845
Resistant: D – Preclinical
|
PF-3845
Resistant: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PF-05212384
Sensitive: D – Preclinical
|
PF-05212384
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
cetuximab
Resistant: D – Preclinical
|
cetuximab
Resistant: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
RTB101
Sensitive: D – Preclinical
|
RTB101
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Thyroid Gland Carcinoma
Thyroid Gland Carcinoma
|
PIK3CA H1047R
PIK3CA H1047R
|
Thyroid Gland Carcinoma
Thyroid Gland Carcinoma
|
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
|
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
GDC-0032
Sensitive: D – Preclinical
|
GDC-0032
Sensitive: D – Preclinical
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
PIK3CA H1047R
PIK3CA H1047R
|
Squamous Cell Carcinoma of Head and Neck
SCCHN
|
cetuximab + RTB101
Sensitive: D – Preclinical
|
cetuximab + RTB101
Sensitive: D – Preclinical
|
